Practical therapeutic drug management in HIV-infected patients: Use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization

被引:39
作者
Neely, Michael [1 ]
Jelliffe, Roger [1 ]
机构
[1] Univ So Calif, Sch Med, Lab Appl Pharmacokinet, Los Angeles, CA USA
关键词
HIV-dose optimization; concentration control;
D O I
10.1177/0091270008321789
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Individualized, model-based, target-oriented optimal concentration-controlled dosing of HIV medications can be beneficial to patients for whom there are limited dosing guidelines, such as children, adolescents, or patients with altered physiologic function. Barriers to this approach include lack of training, expertise, and access to appropriate software to assist the clinician. The authors present 4 illustrative clinical cases of HIV-infected patients whose therapy was optimized using population pharmacokinetic models (here generated from published studies) and supplemented by individualized Bayesian adaptive control of dosage regimens as implemented in the MM-USCPACK software. These 4 cases illustrate how clinicians can maximize therapeutic success in (1) patients with reduced drug clearance, (2) young adolescents transitioning to adult physiology, (3) patients with dose-dependent toxicity, and (4) adolescents with limited therapeutic options.
引用
收藏
页码:1081 / 1091
页数:11
相关论文
共 60 条
  • [1] Methods for integration of pharmacokinetic and phenotypic information in the treatment of infection with human immunodeficiency virus
    Acosta, EP
    King, JR
    [J]. CLINICAL INFECTIOUS DISEASES, 2003, 36 (03) : 373 - 377
  • [2] Position paper on therapeutic drug monitoring of antiretroviral agents
    Acosta, EP
    Gerber, JG
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2002, 18 (12) : 825 - 834
  • [3] A Bayesian approach to tracking patients having changing pharmacokinetic parameters
    Bayard, DS
    Jelliffe, RW
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2004, 31 (01) : 75 - 107
  • [4] BAYARD DS, 1995, SELECTED TOPICS MATH
  • [5] A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients
    Best, Brookie M.
    Goicoechea, Miguel
    Witt, Mallory D.
    Miller, Loren
    Daar, Eric S.
    Diamond, Catherine
    Tilles, Jeremiah G.
    Kemper, Carol A.
    Larsen, Robert
    Holland, Diane T.
    Sun, Shelly
    Jain, Sonia
    Wagner, Glenn
    Capparelli, Edmund V.
    McCutchan, J. Allen
    Haubrich, Richard H.
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 46 (04) : 433 - 442
  • [6] Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens
    Bleyzac, N
    Souillet, G
    Magron, P
    Janoly, A
    Martin, P
    Bertrand, Y
    Galambrun, C
    Dai, Q
    Maire, P
    Jelliffe, RW
    Aulagner, G
    [J]. BONE MARROW TRANSPLANTATION, 2001, 28 (08) : 743 - 751
  • [7] GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy
    Bossi, P
    Peytavin, G
    Ait-Mohand, H
    Delaugerre, C
    Ktorza, N
    Paris, L
    Bonmarchand, M
    Cacace, R
    David, DJ
    Simon, A
    Lamotte, C
    Marcelin, AG
    Calvez, V
    Bricaire, F
    Costagliola, D
    Katlama, C
    [J]. HIV MEDICINE, 2004, 5 (05) : 352 - 359
  • [8] The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity
    Boyd, Mark A.
    Siangphoe, Urnaporn
    Ruxrungtham, Kiat
    Reiss, Peter
    Mahanontharit, Apicha
    Lange, Joep M. A.
    Phanuphak, Praphan
    Cooper, David A.
    Burger, David M.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 57 (06) : 1161 - 1167
  • [9] Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353
    Bryson, Y. J.
    Mirochnick, M.
    Stek, A.
    Mofenson, L. M.
    Connor, J.
    Capparelli, E.
    Watts, D. H.
    Huang, S.
    Hughes, M. D.
    Kaiser, K.
    Purdue, L.
    Asfaw, Y.
    Keller, M.
    Smith, E.
    [J]. HIV CLINICAL TRIALS, 2008, 9 (02): : 115 - 125
  • [10] Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz:: the effect of gender, race, and CYP2B6 polymorphism
    Burger, D
    van der Heiden, I
    la Porte, C
    van der Ende, M
    Groeneveld, P
    Richter, C
    Koopmans, P
    Kroon, F
    Sprenger, H
    Lindemans, J
    Schenk, P
    van Schaik, R
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 61 (02) : 148 - 154